Bangkok Genomics Innovation PCL (BKK:BKGI) EV-to-EBIT : 131.56 (As of Jun. 09, 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bangkok Genomics Innovation PCL EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bangkok Genomics Innovation PCL's Enterprise Value is ฿1,315.51 Mil. Bangkok Genomics Innovation PCL's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ฿10.00 Mil. Therefore, Bangkok Genomics Innovation PCL's EV-to-EBIT for today is 131.56.

The historical rank and industry rank for Bangkok Genomics Innovation PCL's EV-to-EBIT or its related term are showing as below:

BKK:BKGI' s EV-to-EBIT Range Over the Past 10 Years
Min: 32.12 Med: 38.45 Max: 131.56
Current: 131.56

During the past 5 years, the highest EV-to-EBIT of Bangkok Genomics Innovation PCL was 131.56. The lowest was 32.12. And the median was 38.45.

BKK:BKGI's EV-to-EBIT is ranked worse than
97.96% of 98 companies
in the Medical Diagnostics & Research industry
Industry Median: 21.265 vs BKK:BKGI: 131.56

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Bangkok Genomics Innovation PCL's Enterprise Value for the quarter that ended in Mar. 2024 was ฿1,651.51 Mil. Bangkok Genomics Innovation PCL's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ฿10.00 Mil. Bangkok Genomics Innovation PCL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 0.61%.

Bangkok Genomics Innovation PCL EV-to-EBIT Historical Data

The historical data trend for Bangkok Genomics Innovation PCL's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bangkok Genomics Innovation PCL EV-to-EBIT Chart

Bangkok Genomics Innovation PCL Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Bangkok Genomics Innovation PCL Quarterly Data
	Dec20	Dec21	Mar22	Dec22	Mar23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-	-	165.17

Competitive Comparison of Bangkok Genomics Innovation PCL's EV-to-EBIT

For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bangkok Genomics Innovation PCL's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bangkok Genomics Innovation PCL's EV-to-EBIT falls into.

Bangkok Genomics Innovation PCL EV-to-EBIT Calculation

Bangkok Genomics Innovation PCL's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1315.506	/	9.999
	=	131.56

Bangkok Genomics Innovation PCL's current Enterprise Value is ฿1,315.51 Mil.
Bangkok Genomics Innovation PCL's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿10.00 Mil.

Bangkok Genomics Innovation PCL (BKK:BKGI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Bangkok Genomics Innovation PCL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	9.999	/	1651.506
	=	0.61 %

Bangkok Genomics Innovation PCL's Enterprise Value for the quarter that ended in Mar. 2024 was ฿1,651.51 Mil.
Bangkok Genomics Innovation PCL's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿10.00 Mil.

Bangkok Genomics Innovation PCL EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Bangkok Genomics Innovation PCL's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Bangkok Genomics Innovation PCL (BKK:BKGI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bangkok Genomics Innovation PCL (BKK:BKGI) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110

Website

https://www.bangkokgenomics.com

Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products).